{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:29:30Z","timestamp":1794536970426,"version":"4.9.1"},"reference-count":30,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Insulin icodec (icodec) is a novel once-weekly basal insulin analog. This trial investigated two approaches for switching to icodec versus once-daily insulin glargine 100 units\/mL (IGlar U100) in people with type 2 diabetes receiving daily basal insulin and one or more oral glucose-lowering medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>This multicenter, open-label, treat-to-target phase 2 trial randomized (1:1:1) eligible basal insulin\u2013treated (total daily dose 10\u201350 units) people with type 2 diabetes (HbA1c 7.0\u201310.0% [53.0\u201385.8 mmol\/mol]) to icodec with an initial 100% loading dose (in which only the first dose was doubled [icodec LD]), icodec with no loading dose (icodec NLD), or IGlar U100 for 16 weeks. Primary end point was percent time in range (TIR; 3.9\u201310.0 mmol\/L [70\u2013180 mg\/dL]) during weeks 15 and 16, measured using continuous glucose monitoring. Key secondary end points included HbA1c, adverse events (AEs), and hypoglycemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Estimated mean TIR during weeks 15 and 16 was 72.9% (icodec LD; n = 54), 66.0% (icodec NLD; n = 50), and 65.0% (IGlar U100; n = 50), with a statistically significant difference favoring icodec LD versus IGlar U100 (7.9%-points [95% CI 1.8\u201313.9]). Mean HbA1c reduced from 7.9% (62.8 mmol\/mol) at baseline to 7.1% (54.4 mmol\/mol icodec LD) and 7.4% (57.6 mmol\/mol icodec NLD and IGlar U100); incidences and rates of AEs and hypoglycemic episodes were comparable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Switching from daily basal insulin to once-weekly icodec was well tolerated and provided effective glycemic control. Loading dose use when switching to once-weekly icodec significantly increased percent TIR during weeks 15 and 16 versus once-daily IGlar U100, without increasing hypoglycemia risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc20-2877","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T11:10:16Z","timestamp":1618830616000},"page":"1586-1594","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":108,"title":["Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial"],"prefix":"10.2337","volume":"44","clinical-trial-number":[{"clinical-trial-number":"nct03922750","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03751657","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03951805","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1461-1465","authenticated-orcid":false,"given":"Harpreet S.","family":"Bajaj","sequence":"first","affiliation":[{"name":"LMC Diabetes and Endocrinology, Brampton, Ontario, Canada"},{"name":"Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9050-5584","authenticated-orcid":false,"given":"Richard M.","family":"Bergenstal","sequence":"additional","affiliation":[{"name":"International Diabetes Center at Park Nicollet, Medical City, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Christoffersen","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, University of Leicester, Leicester, U.K."},{"name":"NIHR Leicester Biomedical Research Centre, Leicester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amoolya","family":"Gowda","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Isendahl","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S, S\u00f8borg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":false,"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Senior","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Silver","sequence":"additional","affiliation":[{"name":"Southern New Hampshire Diabetes and Endocrinology, Nashua, NH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Trevisan","sequence":"additional","affiliation":[{"name":"Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8324-3275","authenticated-orcid":false,"given":"Julio","family":"Rosenstock","sequence":"additional","affiliation":[{"name":"Dallas Diabetes Research Center, Medical City, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"2022051611144876800_B1","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142020 [published correction appears in Diabetes Care 2020;43:1979]","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"2022051611144876800_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2010.09.010","article-title":"Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes","volume":"60","author":"Nyenwe","year":"2011","journal-title":"Metabolism"},{"key":"2022051611144876800_B3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1185\/03007995.2011.621416","article-title":"Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes","volume":"27","author":"Ross","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2022051611144876800_B4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.diabres.2016.10.003","article-title":"Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: a survey research","volume":"122","author":"Escalada","year":"2016","journal-title":"Diabetes Res Clin Pract"},{"key":"2022051611144876800_B5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2337\/dc09-1184","article-title":"Barriers to insulin initiation: the translating research into action for diabetes insulin starts project","volume":"33","author":"Karter","year":"2010","journal-title":"Diabetes Care"},{"key":"2022051611144876800_B6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","article-title":"Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study","volume":"29","author":"Peyrot","year":"2012","journal-title":"Diabet Med"},{"key":"2022051611144876800_B7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s12325-018-0819-5","article-title":"Addressing clinical inertia in type 2 diabetes mellitus: a review","volume":"35","author":"Okemah","year":"2018","journal-title":"Adv Ther"},{"key":"2022051611144876800_B8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/qjmed\/hcm031","article-title":"Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes","volume":"100","author":"Donnelly","year":"2007","journal-title":"QJM"},{"key":"2022051611144876800_B9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s12325-019-00925-6","article-title":"Differentiating basal insulin preparations: understanding how they work explains why they are different","volume":"36","author":"Cheng","year":"2019","journal-title":"Adv Ther"},{"key":"2022051611144876800_B10","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/j.dsx.2019.05.001","article-title":"Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: a critical appraisal","volume":"13","author":"Hernando","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"2022051611144876800_B11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1463-1326.2010.01327.x","article-title":"Patient perspectives on once-weekly medications for diabetes","volume":"13","author":"Polonsky","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022051611144876800_B12","doi-asserted-by":"crossref","first-page":"237-OR","DOI":"10.2337\/db20-237-OR","article-title":"Insulin icodec, an insulin analog suited for once-weekly dosing in type 2 diabetes (Abstract)","volume":"69","author":"H\u00f6velmann","year":"2020","journal-title":"Diabetes"},{"key":"2022051611144876800_B13","doi-asserted-by":"crossref","first-page":"236-OR","DOI":"10.2337\/db20-236-OR","article-title":"Molecular and biological properties of insulin icodec, a new insulin analog designed to give a long half-life suitable for once-weekly dosing (Abstract)","volume":"69","author":"Nishimura","year":"2020","journal-title":"Diabetes"},{"key":"2022051611144876800_B14","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2022474","article-title":"Once-weekly insulin for type 2 diabetes without previous insulin treatment","volume":"383","author":"Rosenstock","year":"2020","journal-title":"N Engl J Med"},{"key":"2022051611144876800_B15","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.2337\/dc19-S006","article-title":"6. Glycemic targets: Standards of Medical Care in Diabetes\u20142019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"2022051611144876800_B16","volume-title":"Statistical Analysis with Missing Data","author":"Little","year":"1987"},{"key":"2022051611144876800_B17","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"key":"2022051611144876800_B18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1177\/1932296818822496","article-title":"The relationships between time in range, hyperglycemia metrics, and HbA1c","volume":"13","author":"Beck","year":"2019","journal-title":"J Diabetes Sci Technol"},{"key":"2022051611144876800_B19","doi-asserted-by":"crossref","first-page":"400","DOI":"10.2337\/dc18-1444","article-title":"Validation of time in range as an outcome measure for diabetes clinical trials","volume":"42","author":"Beck","year":"2019","journal-title":"Diabetes Care"},{"key":"2022051611144876800_B20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1089\/dia.2019.0251","article-title":"Time in range is associated with carotid intima-media thickness in type 2 diabetes","volume":"22","author":"Lu","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"2022051611144876800_B21","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.2337\/dc18-1131","article-title":"Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes","volume":"41","author":"Lu","year":"2018","journal-title":"Diabetes Care"},{"key":"2022051611144876800_B22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1089\/dia.2018.0310","article-title":"The relationship of hemoglobin A1C to time-in-range in patients with diabetes","volume":"21","author":"Vigersky","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"2022051611144876800_B23","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"2022051611144876800_B24","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12325-016-0470-y","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a medicare population","volume":"34","author":"Nguyen","year":"2017","journal-title":"Adv Ther"},{"key":"2022051611144876800_B25","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jdi.12906","article-title":"Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: a randomized controlled trial","volume":"10","author":"Takase","year":"2019","journal-title":"J Diabetes Investig"},{"key":"2022051611144876800_B26","first-page":"382","article-title":"Impact of glycemic control on healthcare resource utilization and costs of type 2 diabetes: current and future pharmacologic approaches to improving outcomes","volume":"6","author":"Banerji","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"2022051611144876800_B27","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2147\/PPA.S107543","article-title":"Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database","volume":"10","author":"Boye","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"2022051611144876800_B28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s13300-013-0034-y","article-title":"Adherence to therapies in patients with type 2 diabetes","volume":"4","author":"Garc\u00eda-P\u00e9rez","year":"2013","journal-title":"Diabetes Ther"},{"key":"2022051611144876800_B29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pcd.2016.09.003","article-title":"Clinical inertia to insulin initiation and intensification in the UK: a focused literature review","volume":"11","author":"Khunti","year":"2017","journal-title":"Prim Care Diabetes"},{"key":"2022051611144876800_B30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-015-0260-x","article-title":"Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes","volume":"14","author":"Paul","year":"2015","journal-title":"Cardiovasc Diabetol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc20-2877","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/7\/1586\/633028\/dc202877.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/7\/1586\/633028\/dc202877.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T07:15:36Z","timestamp":1652685336000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/44\/7\/1586\/138808\/Switching-to-Once-Weekly-Insulin-Icodec-Versus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,3,19]]},"published-print":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc20-2877","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.14043746.v1","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.14043746","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.14043746.v2","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,19]]}}}